News for H. Lundbeck A/S (HLUKF)

NervGen Pharma appoints Dr. Randall Kaye as Chief Medical Advisor following successful Phase 1b/2a NVG-291 trial results. Dr. Kaye has extensive experie

Lundbeck’s strong Q1, undervaluation, and pipeline potential offset policy and clinical risks, with upside tied to key catalysts. Find out why HLBBF stock is a buy.

May 14, 2025 / 11:00AM GMTOperator Ladies and gentlemen, welcome to the Lundbeck A/S financial statement for the first three months of the 2025 conference call.

PR NewswireVALBY, Denmark, May 6, 2025 VALBY, Denmark, May 6, 2025 /PRNewswire/ -- H. Lundbeck A/S is pleased to announce its agreement with the Danish Cen

PR NewswireVALBY, Denmark, April 4, 2025 VALBY, Denmark, April 4, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present positive interim results fro

PR NewswireVALBY, Denmark, March 10, 2025 VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has gra

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).

PR NewswireVALBY, Denmark, Feb. 12, 2025 The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatmen

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with successful clinical trials.

PR NewswireVALBY, Denmark, Dec. 5, 2024 Longboard Pharmaceuticals, now a wholly owned subsidiary of Lundbeck, presents scientific data in multiple poster p

According to Research by SNS Insider, The Antipsychotic Drugs Market is Expected to Grow at a CAGR of 6.53% Through 2032, Supported by Increasing...

Increasing prevalence of anxiety and depression, coupled with innovation in pharmaceutical treatments and growing demand for mental health solutions, fuels...

S&P Global's Joe Mantone puts the latest M&A data in perspective and how deal pros might react post-Election Day.

According to a report by Fortune Business Insights, the U.S. Autism Spectrum Disorder Therapeutics Market size sector reached a market value of USD 1.04 Billion in 2022. Future projections show a…

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

BALA CYNWYD, Penn., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish...

The rising incidence of Alzheimer's and other tau-related disorders, driven by an aging global population, is significantly boosting the demand for...

Huntingtons disease treatment industry is projected to witness a CAGR of 20.8% during the period 2024-2032. This growth can be attributed to the limited...